Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders

Franz Felix Konen; Nora Möhn; Torsten Witte; Matthias Schefzyk; Miriam Wiestler; Svjetlana Lovric; Karsten Hufendiek; Philipp Schwenkenbecher; Kurt-Wolfram Sühs; Manuel A Friese; Luisa Klotz; Refik Pul; Marc Pawlitzki; David Hagin; Christoph Kleinschnitz; Sven G Meuth; Thomas Skripuletz

doi:10.1016/j.autrev.2023.103312

Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders

Standard

Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. / Konen, Franz Felix; Möhn, Nora; Witte, Torsten; Schefzyk, Matthias; Wiestler, Miriam; Lovric, Svjetlana; Hufendiek, Karsten; Schwenkenbecher, Philipp; Sühs, Kurt-Wolfram; Friese, Manuel A; Klotz, Luisa; Pul, Refik; Pawlitzki, Marc; Hagin, David; Kleinschnitz, Christoph; Meuth, Sven G; Skripuletz, Thomas.

In: AUTOIMMUN REV, Vol. 22, No. 5, 05.2023, p. 103312.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Konen, FF, Möhn, N, Witte, T, Schefzyk, M, Wiestler, M, Lovric, S, Hufendiek, K, Schwenkenbecher, P, Sühs, K-W, Friese, MA, Klotz, L, Pul, R, Pawlitzki, M, Hagin, D, Kleinschnitz, C, Meuth, SG & Skripuletz, T 2023, 'Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders', AUTOIMMUN REV, vol. 22, no. 5, pp. 103312. https://doi.org/10.1016/j.autrev.2023.103312

APA

Konen, F. F., Möhn, N., Witte, T., Schefzyk, M., Wiestler, M., Lovric, S., Hufendiek, K., Schwenkenbecher, P., Sühs, K-W., Friese, M. A., Klotz, L., Pul, R., Pawlitzki, M., Hagin, D., Kleinschnitz, C., Meuth, S. G., & Skripuletz, T. (2023). Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. AUTOIMMUN REV, 22(5), 103312. https://doi.org/10.1016/j.autrev.2023.103312

Vancouver

Konen FF, Möhn N, Witte T, Schefzyk M, Wiestler M, Lovric S et al. Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. AUTOIMMUN REV. 2023 May;22(5):103312. https://doi.org/10.1016/j.autrev.2023.103312

Bibtex

@article{2a0ac03a0ec24ca89370f3a4d07b2f48,

title = "Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders",

abstract = "More than 10 disease-modifying therapies (DMT) are approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS) and new therapeutic options are on the horizon. Due to different underlying therapeutic mechanisms, a more individualized selection of DMTs in MS is possible, taking into account the patient's current situation. Therefore, concomitant treatment of various comorbid conditions, including autoimmune mediated disorders such as rheumatoid arthritis, should be considered in MS patients. Because the pathomechanisms of autoimmunity partially overlap, DMT could also treat concomitant inflammatory diseases and simplify the patient's treatment. In contrast, the exacerbation and even new occurrence of several autoimmune diseases have been reported as a result of immunomodulatory treatment of MS. To simplify treatment and avoid disease exacerbation, knowledge of the beneficial and adverse effects of DMT in other autoimmune disorders is critical. Therefore, we conducted a literature search and described the beneficial and adverse effects of approved and currently studied DMT in a large number of comorbid autoimmune diseases, including rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases, cutaneous disorders including psoriasis, Sj{\"o}gren´s syndrome, systemic lupus erythematosus, systemic vasculitis, autoimmune hepatitis, and ocular autoimmune disorders. Our review aims to facilitate the selection of an appropriate DMT in patients with MS and comorbid autoimmune diseases.",

author = "Konen, {Franz Felix} and Nora M{\"o}hn and Torsten Witte and Matthias Schefzyk and Miriam Wiestler and Svjetlana Lovric and Karsten Hufendiek and Philipp Schwenkenbecher and Kurt-Wolfram S{\"u}hs and Friese, {Manuel A} and Luisa Klotz and Refik Pul and Marc Pawlitzki and David Hagin and Christoph Kleinschnitz and Meuth, {Sven G} and Thomas Skripuletz",

year = "2023",

month = may,

doi = "10.1016/j.autrev.2023.103312",

language = "English",

volume = "22",

pages = "103312",

journal = "AUTOIMMUN REV",

issn = "1568-9972",

publisher = "Elsevier",

number = "5",

}

RIS

TY - JOUR

T1 - Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders

AU - Konen, Franz Felix

AU - Möhn, Nora

AU - Witte, Torsten

AU - Schefzyk, Matthias

AU - Wiestler, Miriam

AU - Lovric, Svjetlana

AU - Hufendiek, Karsten

AU - Schwenkenbecher, Philipp

AU - Sühs, Kurt-Wolfram

AU - Friese, Manuel A

AU - Klotz, Luisa

AU - Pul, Refik

AU - Pawlitzki, Marc

AU - Hagin, David

AU - Kleinschnitz, Christoph

AU - Meuth, Sven G

AU - Skripuletz, Thomas

PY - 2023/5

Y1 - 2023/5

N2 - More than 10 disease-modifying therapies (DMT) are approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS) and new therapeutic options are on the horizon. Due to different underlying therapeutic mechanisms, a more individualized selection of DMTs in MS is possible, taking into account the patient's current situation. Therefore, concomitant treatment of various comorbid conditions, including autoimmune mediated disorders such as rheumatoid arthritis, should be considered in MS patients. Because the pathomechanisms of autoimmunity partially overlap, DMT could also treat concomitant inflammatory diseases and simplify the patient's treatment. In contrast, the exacerbation and even new occurrence of several autoimmune diseases have been reported as a result of immunomodulatory treatment of MS. To simplify treatment and avoid disease exacerbation, knowledge of the beneficial and adverse effects of DMT in other autoimmune disorders is critical. Therefore, we conducted a literature search and described the beneficial and adverse effects of approved and currently studied DMT in a large number of comorbid autoimmune diseases, including rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases, cutaneous disorders including psoriasis, Sjögren´s syndrome, systemic lupus erythematosus, systemic vasculitis, autoimmune hepatitis, and ocular autoimmune disorders. Our review aims to facilitate the selection of an appropriate DMT in patients with MS and comorbid autoimmune diseases.

AB - More than 10 disease-modifying therapies (DMT) are approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS) and new therapeutic options are on the horizon. Due to different underlying therapeutic mechanisms, a more individualized selection of DMTs in MS is possible, taking into account the patient's current situation. Therefore, concomitant treatment of various comorbid conditions, including autoimmune mediated disorders such as rheumatoid arthritis, should be considered in MS patients. Because the pathomechanisms of autoimmunity partially overlap, DMT could also treat concomitant inflammatory diseases and simplify the patient's treatment. In contrast, the exacerbation and even new occurrence of several autoimmune diseases have been reported as a result of immunomodulatory treatment of MS. To simplify treatment and avoid disease exacerbation, knowledge of the beneficial and adverse effects of DMT in other autoimmune disorders is critical. Therefore, we conducted a literature search and described the beneficial and adverse effects of approved and currently studied DMT in a large number of comorbid autoimmune diseases, including rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases, cutaneous disorders including psoriasis, Sjögren´s syndrome, systemic lupus erythematosus, systemic vasculitis, autoimmune hepatitis, and ocular autoimmune disorders. Our review aims to facilitate the selection of an appropriate DMT in patients with MS and comorbid autoimmune diseases.

U2 - 10.1016/j.autrev.2023.103312

DO - 10.1016/j.autrev.2023.103312

M3 - SCORING: Review article

C2 - 36924922

VL - 22

SP - 103312

JO - AUTOIMMUN REV

JF - AUTOIMMUN REV

SN - 1568-9972

IS - 5

ER -